Functional significance of adenosine 5′-diphosphate receptor (P2Y12) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibα induced by conditions of high shear rate

Circulation

Volumn 105, Issue 21, 2002, Pages 2531-2536

  Goto, Shinya ^a   Tamura, Noriko ^a   Eto, Koji ^a   Ikeda, Yasuo ^a   Handa, Shunnosuke ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glycoproteins; Platelets; Receptors; Thrombosis; Von Willebrand factor

Indexed keywords

ADENOSINE PHOSPHATE; GLYCOPROTEIN IB; PADGEM PROTEIN; PURINE P2Y RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD SAMPLING; CHEMICAL INTERACTION; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SHEAR RATE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; VISCOMETER;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; CELL ADHESION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; MICROSCOPY, VIDEO; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; RECEPTORS, PURINERGIC P2; STRESS, MECHANICAL; VON WILLEBRAND FACTOR;

EID: 0037188563     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000016703.93845.AF     Document Type: Article

References (34)

1. Ticlopidine and clopidogrel
2. Identification of the platelet ADP receptor targeted by antithrombotic drugs
3. The anti-aggregating activity of clopidogrel is due to ametabolic activation by the hepatic cytochrome P450-1A
4. ADP receptors and clinical bleeding disorders
5. Molecular basis for ADP-induced platelet activation, I: Evidence for three distinct ADP receptors on human platelets
6. ADP and platelets: The end of the beginning
7. Role of intracellular signaling events in ADP-induced platelet aggregation
8. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
9. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
10. Role of intracellular signaling events in ADP-induced platelet aggregation
11. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel
12. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain
13. Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor
14. Enhanced shear-induced platelet aggregation in acute myocardial infarction
15. Antagonists of the platelet P2T-receptor: A novel approach to antithrombotic therapy
16. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow condition
17. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress
18. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets
19. Platelet surface P-selectin molecules increased after exposing platelets to a high shear flow
20. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles
21. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib: Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments
22. Conformational changes in the A1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Ibalpha
23. Two distinct mechanisms are involved in stent thrombosis under flow conditions
24. Changes in the platelet membrane glycoprotein IIb. IIIa complex during platelet activation
25. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood
26. Coronary thrombosis: Effects of blood flow on the mechanism of thrombus formation
27. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets
28. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow
29. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine
30. Shear-induced platelet aggregation in cerebral ischemia
31. Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention
32. Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation
33. Blockade of adenosine diphosphate receptor P2Y12 and P2Y1 is required to inhibit platelet aggregation in whole blood under flow
34. Effects of clopidogrel on platelet activation and coagulation of non-anticoagulated rat blood under high shear stress